Progenics Pharmaceuticals News

Progenics Pharmaceuticals Aktie VALOR 552781 / ISIN US7431871067

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

08.06.09	Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical (Businesswire)
04.02.09	Progenics Appoints Peter J. Crowley as Independent Board Member (Businesswire)
04.02.09	Progenics Appoints Peter J. Crowley as Independent Board Member (Businesswire)
10.11.08	Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates (Businesswire)
04.11.08	Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development (Businesswire)
08.08.08	Progenics Pharmaceuticals Reports Second Quarter 2008 Results (Businesswire)
03.07.08	Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients (Businesswire)
09.05.08	CORRECTING and REPLACING Progenics Pharmaceuticals Reports First Quarter 2008 Results (Businesswire)
09.05.08	Progenics Pharmaceuticals Reports First Quarter 2008 Results (Businesswire)
24.04.08	Progenics and Wyeth Announce FDA Has Approved RELISTOR (Businesswire)
01.11.07	Progenics Awarded $1.9 Million in NIH Grants for Novel Prostate Cancer Therapies (Businesswire)
15.10.07	Wyeth and Progenics to Initiate Phase 2 Trials of Oral Methylnaltrexone in Chronic-pain Setting (Businesswire)
25.07.07	Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting (Businesswire)
16.03.05	Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	265.50	2.04 %	K V
Lonza Grp	569.20	1.43 %	K V
Novartis	94.03	1.40 %	K V
Geberit	613.00	0.79 %	K V
Part Grp Hldg	1’102.00	0.78 %	K V
CieFinRichemont	154.85	-0.67 %	K V
Kuehne+Nagel Int	185.05	-0.80 %	K V
ABB	46.54	-1.61 %	K V
Logitech Intl	68.44	-2.34 %	K V
Holcim	91.02	-2.57 %	K V